Innovus Pharmaceuticals has enrolled the first subject in a clinical trial designed to assess the effect and tolerance of musclin on muscle health.

The open-label, uncontrolled, ascending dose trial aims to include up to 20 healthy adults and is currently being conducted at a single site in the US.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Musclin is a dietary supplement that includes thymol and bioperine. It supports muscle mass, muscle recovery time, and improve endurance levels in adults.

Subjects will receive a daily dose of two musclin capsules for 30 days as part of the trial.

“This study represents part of Innovus Pharma’s strategy to leverage cutting-edge technologies that have been developed by pioneers in the field of muscle health.”

The completion of the 30-day period means the subjects will receive four capsules of musclin for an additional 30 days.

The primary objective of the trial is to evaluate the tolerance of musclin, while additional aims comprise self-reported changes in energy and stamina levels.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Innovus Pharma president and CEO Bassam Damaj said: “This study represents part of Innovus Pharma’s strategy to leverage cutting-edge technologies that have been developed by pioneers in the field of muscle health and introduce clinically-tested and proven products to consumers.

“As a result of its unique mechanism of action on muscle fibres, we believe musclin is one of the few products targeting the muscle fibres specifically and not the whole body protein synthesis pathways.

“We are hoping results from this study and potentially others to come will help to support individuals who want to maintain optimal muscle health as they age or suffer from muscle weaknesses.”

The trial plans to complete and publish results from the trial in the first half of next year.